Iloprost Ratiopharm (Iloprost)

Iloprost mimics the natural prostacyclin molecule and activates IP receptors on vascular smooth‑muscle cells. This activation raises intracellular cAMP levels, causing the muscles to relax, which leads to vasodilation, reduced platelet aggregation, and inhibition of abnormal vascular cell growth.

The specific dose and infusion schedule of Iloprost Ratiopharm are determined by the prescribing physician based on the patient’s condition, severity, and response to therapy. Dosing is individualized and should follow the prescriber’s written instructions.

The safety of Iloprost in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and any required import documentation.

Iloprost belongs to the prostacyclin analog class, offering direct vasodilation and antiplatelet effects. Compared with oral endothelin receptor antagonists or phosphodiesterase‑5 inhibitors, Iloprost provides rapid, short‑acting pulmonary vasodilation via intravenous or subcutaneous routes, which can be advantageous for patients needing acute hemodynamic control.

Iloprost Ratiopharm should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The product should remain in its original packaging until use to maintain stability and potency.

Iloprost is supplied as a sterile solution for injection and can be given intravenously or subcutaneously. Administration is typically performed by a healthcare professional using an infusion pump or syringe, following the dosing schedule prescribed by the treating physician.

Serious risks include severe hypotension, pulmonary edema, and significant bleeding. Patients should be closely monitored for sudden drops in blood pressure, respiratory distress, or signs of hemorrhage, and therapy should be adjusted or discontinued if these events occur.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation, those with uncontrolled systemic hypertension, and individuals experiencing active bleeding or severe hypotension. Clinical judgment is required for patients with significant cardiac or pulmonary instability.